The Growing Consumer Demand for Online Health Video

Manhattan ResearchPharmaceutical and healthcare market research company Manhattan Research releases its latest report, "Consumer Online Health Video: Understanding Consumption Patterns to Optimize Implementation". This report explores consumer demand for online health video and the impact of this format on health behavior. Adoption of online health video has increased significantly among U.S. consumers online for prescription drug information in particular, growing from 21% in 2007 to 48% in 2009. The report also details where consumers watch health video and which genres they prefer, as well as the challenges and opportunities in leveraging YouTube. For example, marketers should be aware that significantly more consumers watch online health video on general health and news websites than on YouTube.

"Optimizing online health video investments can be tricky," said Monique Levy, Senior Director of Research at Manhattan Research and lead author of the report. "Consumers tend to watch health video where they are already getting health information and don't necessarily go online intending to find health video, suggesting a distributed video strategy is best. However, this approach is often more costly than investing in a single channel."

"Consumer Online Health Video: Understanding Consumption Patterns to Optimize Implementation" is from Manhattan Research's ePharma Consumer® v9.0 study, which is focused on the attitudes and behaviors of consumers seeking pharmaceutical information online. The study was conducted via online survey in Q4 2009 among 6,575 U.S. adults (age 18+).

For more information about the report and its table of contents, please visit http://www.manhattanresearch.com/online-health-video.

About Manhattan Research Reports
Manhattan Research offers in-depth reports on important trends in physician and consumer use of digital media and technology for health. The report series draws from interviews conducted with nearly 20,000 physicians and consumers about their behaviors, attitudes, and future interests as it relates to their use of the Internet and other technologies for health and treatment decisions. Each PDF report includes a written analysis, supporting graphs and data, and strategic takeaways. For more information, please visit http://www.manhattanresearch.com/reports.

About Manhattan Research
Manhattan Research, a Decision Resources, Inc. company, is a leading market research and advisory services firm for global pharmaceutical and healthcare companies. For more information, visit www.manhattanresearch.com.

About Decision Resources, Inc.
Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.decisionresourcesinc.com.

Most Popular Now

Regorafenib to be tested in brain cancer patients …

Bayer announced that the regorafenib arm of the platform trial "GBM AGILE" (Glioblastoma Adaptive Global Innovative Learning Environment) opened for enrollment in the US ...

Sanofi and Google to develop new healthcare Innova…

Sanofi and Google will establish a new virtual Innovation Lab with the ambition to radically transform how future medicines and health services are delivered by tapping i...

Bristol-Myers Squibb provides update on pending me…

Bristol-Myers Squibb Company (NYSE: BMY) today provided an update on the approval process and timeline for the Company’s pending merger with Celgene Corporation (NASDAQ: ...

Japan becomes the first country to approve Roche's…

Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has approved Rozlytrek® (entrectinib) for the treatment of a...

Breztri Aerosphere (PT010) approved in Japan for p…

AstraZeneca announced that Breztri Aerosphere (budesonide/glycopyrronium/ formoterol fumarate), formerly PT010, has been approved in Japan as a triple-combination therapy...

FDA approves Amgen and Allergan's KANJINTITM (tras…

Amgen (NASDAQ:AMGN) and Allergan plc (NYSE:AGN) announced that the U.S. Food and Drug Administration (FDA) has approved KANJINTITM (trastuzumab-anns) for all approved ind...

Vitamin D may not help your heart

While previous research has suggested a link between low levels of vitamin D in the blood and an increased risk of cardiovascular disease, a new Michigan State University...

Human-on-a-chip model tests cancer drug efficacy a…

A reconfigurable "body-on-a-chip" model could transform drug development by simultaneously measuring compound efficacy and toxicity, for both target cells and other organ...

Pathogen engineered to self-destruct underlies can…

A team of investigators has developed a cancer vaccine technology using live, attenuated pathogens as vectors. A feature of the vaccine causes these bacteria to self-dest...

Artificial DNA can control release of active ingre…

A drug with three active ingredients that are released in sequence at specific times: Thanks to the work of a team at the Technical University of Munich (TUM), what was o...

How gastric stem cells fight bacteria

Stem cells are not only key players in tissue regeneration, they are also capable of taking direct action against bacteria. This is the finding of a study conducted by re...

Researchers identify enzyme that suppresses immune…

Immunotherapies have transformed cancer care, but their successes have been limited for reasons that are both complex and perplexing. In breast cancer especially, only a ...